NCT06085755View on ClinicalTrials.gov

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Stomach Neoplasm
Interventions
DRUG

Trastuzumab deruxtecan

Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.

DRUG

Afatinib

Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.

Trial Locations (1)

Unknown

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Jeeyun Lee

OTHER